The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the Medicare Program International Pricing Index Model for Medicare Part B Drugs pre-poposed rule
The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the Medicare Program International Pricing Index Model for Medicare Part B Drugs pre-poposed rule. They write that despite their concern over rising drug prices and high costs of cancer care, they do not support a mandatory, national experiment on patient care. They add that they have serious concerns about the impact of the model on the care received by patients with cancer, the impacticality of its design, and its legaltiy. Based on these concerns, COA urges CMS to not move foward with the proposal.
Read the full comment letter.
GLP-1 Receptor Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival
August 2nd 2025Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.
Read More